INMB · Inmune Bio, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $50.0K | - | - | - | $14.0K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $3.64M | - | $4.89M | $5.80M | $7.64M | - | $10.07M | $7.05M | $8.69M | - |
| SG&A | $2.17M | - | $2.55M | $2.25M | $2.32M | - | $2.22M | $2.81M | $2.34M | - |
| Total Operating Expenses | $5.81M | - | $7.43M | $24.57M | $9.96M | - | $12.29M | $9.87M | $11.03M | - |
| D&A | $52.0K | - | - | - | - | - | - | - | - | - |
| Operating Income | ($5.81M) | - | ($7.43M) | ($24.57M) | ($9.90M) | - | ($12.29M) | ($9.87M) | ($11.02M) | - |
| Interest Expense | - | - | $145.00M | $250.0K | $0 | - | $145.0K | $631.0K | $357.0K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($5.41M) | - | ($6.47M) | ($24.46M) | ($9.74M) | - | ($12.09M) | ($9.75M) | ($11.03M) | - |
| EPS - Basic | ($0.20) | - | ($0.24) | ($1.05) | ($0.43) | - | ($0.60) | ($0.50) | ($0.61) | - |
| EPS - Diluted | ($0.20) | - | ($0.24) | ($1.05) | ($0.43) | - | ($0.60) | ($0.50) | ($0.61) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $21.36M | $24.75M | $27.73M | $33.37M | $19.34M | $20.92M | $33.55M | $31.07M | $26.00M | $35.85M |
| Accounts Receivable | $479.0K | $4.28M | $1.70M | $1.60M | $1.28M | $1.18M | $1.11M | $3.14M | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $22.82M | $29.89M | $30.67M | $36.03M | $20.96M | $22.66M | $35.85M | $35.49M | $29.82M | $39.94M |
| Total Assets | $25.82M | $32.35M | $33.36M | $37.68M | $37.80M | $39.56M | $52.78M | $52.45M | $46.83M | $57.00M |
| Current Liabilities | $5.39M | $8.42M | $7.36M | $8.59M | $7.93M | $7.22M | $13.82M | $15.05M | $17.45M | $18.46M |
| Long-term Debt | - | - | - | $15.00M | $15.00M | $15.00M | - | $15.00M | - | - |
| Total Liabilities | $6.19M | $8.83M | $7.98M | $8.82M | $8.13M | $7.46M | $14.11M | $15.37M | $17.81M | $18.86M |
| Stockholders' Equity | $19.62M | $23.52M | $25.38M | $28.87M | $29.67M | $32.10M | $38.67M | $36.28M | $28.22M | $37.34M |
| Retained Earnings | ($214.44M) | ($209.04M) | ($203.77M) | ($197.30M) | ($172.84M) | ($163.10M) | ($153.89M) | ($141.79M) | ($132.05M) | ($121.02M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.40M) | - | - | - | ($6.82M) | - | - | - | ($7.48M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | $5.27M | - | - | - | ($2.50M) | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | -19810.0% | - | - | - | -78692.9% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | -19478.0% | - | - | - | -78750.0% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | 15278.0% | - | - | - | 62092.9% | - |
| SG&A / Revenue | - | - | - | - | 4632.0% | - | - | - | 16700.0% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -20.9% | - | -19.4% | -64.9% | -25.8% | - | -22.9% | -18.6% | -23.5% | - |
| Return on equity | -27.6% | - | -25.5% | -84.7% | -32.8% | - | -31.3% | -26.9% | -39.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.24 | 3.55 | 4.17 | 4.20 | 2.64 | 3.14 | 2.59 | 2.36 | 1.71 | 2.16 |
| Quick ratio | 4.24 | 3.55 | 4.17 | 4.20 | 2.64 | 3.14 | 2.59 | 2.36 | 1.71 | 2.16 |
| Cash ratio | 3.96 | 2.94 | 3.77 | 3.89 | 2.44 | 2.90 | 2.43 | 2.06 | 1.49 | 1.94 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | 0.52 | 0.51 | 0.47 | - | 0.41 | - | - |
| Debt / Assets | - | - | - | 0.40 | 0.40 | 0.38 | - | 0.29 | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | -0.1x | -98.3x | - | - | -84.7x | -15.6x | -30.9x | - |
| Equity multiplier | 1.32 | 1.38 | 1.31 | 1.31 | 1.27 | 1.23 | 1.36 | 1.45 | 1.66 | 1.53 |
| Liabilities / Assets | 0.24 | 0.27 | 0.24 | 0.23 | 0.22 | 0.19 | 0.27 | 0.29 | 0.38 | 0.33 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | 0.00 | - | - | - | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | 9366d | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 1.5x | - | 2.2x | 1.9x | 5.9x | - | 2.8x | 4.7x | 7.5x | - |
| P / S | - | - | - | - | 3513.9x | - | - | - | 15129.4x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | 257.1% | - | - | - | -63.2% | - |
| Revenue CAGR (3y) | - | - | - | - | -32.6% | - | - | - | 51.8% | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 41.3% | - | 39.5% | -149.1% | 10.1% | - | -44.1% | -53.9% | -71.5% | - |
| Net income growth (YoY) | 44.5% | - | 46.5% | -151.0% | 11.7% | - | -41.2% | -49.9% | -68.7% | - |
| EPS growth (YoY) | 53.5% | - | 60.0% | -110.0% | 29.5% | - | -25.0% | -31.6% | -69.4% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -33.9% | -26.7% | -34.4% | -20.4% | 5.1% | -14.0% | -12.0% | -28.4% | -49.0% | -37.9% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Inmune Bio against the 5 most active filers in the same SIC group.